中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2012年
12期
1010-1014
,共5页
曹其伟%李红燕%姚晓香%王晋芬
曹其偉%李紅燕%姚曉香%王晉芬
조기위%리홍연%요효향%왕진분
淋巴瘤,大细胞,弥漫型%微RNA%复发%逆转录聚合酶链反应%生物学标记
淋巴瘤,大細胞,瀰漫型%微RNA%複髮%逆轉錄聚閤酶鏈反應%生物學標記
림파류,대세포,미만형%미RNA%복발%역전록취합매련반응%생물학표기
Lymphoma,large cell,diffuse%MicroRNAs%Recurrence%Reverse transcriptase polymerase chain reaction%Biological markers
目的 探讨hsa-miR-146b-5p(miR-146b-5p)的表达在弥漫大B细胞淋巴瘤(DLBCL)患者风险评估中的意义.方法 选择62例原发于淋巴结的DLBCL患者石蜡样本,应用免疫组织化学EnVision法对所有样本进行CD20、CD3、CD10、Bcl-6、Mum-1免疫标记,根据Han's分类方法将DLBCL分为生发中心B细胞型(GCB型)和非生发中心B细胞型(non-GCB型);应用安捷伦16.0高密度芯片对24例DLBCL患者的石蜡样本进行miRNA表达谱筛选;采用实时定量RT-PCR方法对62例DLBCL患者的石蜡样本进行miR-146b-5p表达水平的验证.以11例淋巴结反应性增生患者标本作为对照.结果 62例DLBCL患者中,GCB型22例(35.5%),non-GCB型40例(64.5%),GCB型患者中miR-146b-5p表达水平是non-GCB型患者的3.2倍,差异有统计学意义(P=0.006).DLBCL患者中miR-146b-5p表达水平是淋巴结反性增生患者的5.4倍,差异有统计学意义(P=0.001).62例DLBCL患者中,复发者35例(56.5%).无复发组患者的miR-146b-5p表达水平明显高于复发组,差异有统计学意义(P=0.004).DLBCL患者中miR-146b-5p高表达组(>中位值)无复发生存(RFS)率明显高于低表达组(<中位值),差异有统计学意义(P=0.005),miR-146b-5p的表达与患者总体生存(OS)率没有明显相关性.多因素COX模型分析显示 miR-146b-5p低表达(P=0.004)、国际预后指数(IPI)≥3分(P=0.011)为各自独立的预后不良因素.结论 DLBCL患者无复发组miR-146b-5p的表达水平明显高于复发组,并且miR-146b-5p高表达组RFS率明显高于低表达组.提示miR-146b-5p可能是DLBCL患者风险评估中的一个新型分子标志物.
目的 探討hsa-miR-146b-5p(miR-146b-5p)的錶達在瀰漫大B細胞淋巴瘤(DLBCL)患者風險評估中的意義.方法 選擇62例原髮于淋巴結的DLBCL患者石蠟樣本,應用免疫組織化學EnVision法對所有樣本進行CD20、CD3、CD10、Bcl-6、Mum-1免疫標記,根據Han's分類方法將DLBCL分為生髮中心B細胞型(GCB型)和非生髮中心B細胞型(non-GCB型);應用安捷倫16.0高密度芯片對24例DLBCL患者的石蠟樣本進行miRNA錶達譜篩選;採用實時定量RT-PCR方法對62例DLBCL患者的石蠟樣本進行miR-146b-5p錶達水平的驗證.以11例淋巴結反應性增生患者標本作為對照.結果 62例DLBCL患者中,GCB型22例(35.5%),non-GCB型40例(64.5%),GCB型患者中miR-146b-5p錶達水平是non-GCB型患者的3.2倍,差異有統計學意義(P=0.006).DLBCL患者中miR-146b-5p錶達水平是淋巴結反性增生患者的5.4倍,差異有統計學意義(P=0.001).62例DLBCL患者中,複髮者35例(56.5%).無複髮組患者的miR-146b-5p錶達水平明顯高于複髮組,差異有統計學意義(P=0.004).DLBCL患者中miR-146b-5p高錶達組(>中位值)無複髮生存(RFS)率明顯高于低錶達組(<中位值),差異有統計學意義(P=0.005),miR-146b-5p的錶達與患者總體生存(OS)率沒有明顯相關性.多因素COX模型分析顯示 miR-146b-5p低錶達(P=0.004)、國際預後指數(IPI)≥3分(P=0.011)為各自獨立的預後不良因素.結論 DLBCL患者無複髮組miR-146b-5p的錶達水平明顯高于複髮組,併且miR-146b-5p高錶達組RFS率明顯高于低錶達組.提示miR-146b-5p可能是DLBCL患者風險評估中的一箇新型分子標誌物.
목적 탐토hsa-miR-146b-5p(miR-146b-5p)적표체재미만대B세포림파류(DLBCL)환자풍험평고중적의의.방법 선택62례원발우림파결적DLBCL환자석사양본,응용면역조직화학EnVision법대소유양본진행CD20、CD3、CD10、Bcl-6、Mum-1면역표기,근거Han's분류방법장DLBCL분위생발중심B세포형(GCB형)화비생발중심B세포형(non-GCB형);응용안첩륜16.0고밀도심편대24례DLBCL환자적석사양본진행miRNA표체보사선;채용실시정량RT-PCR방법대62례DLBCL환자적석사양본진행miR-146b-5p표체수평적험증.이11례림파결반응성증생환자표본작위대조.결과 62례DLBCL환자중,GCB형22례(35.5%),non-GCB형40례(64.5%),GCB형환자중miR-146b-5p표체수평시non-GCB형환자적3.2배,차이유통계학의의(P=0.006).DLBCL환자중miR-146b-5p표체수평시림파결반성증생환자적5.4배,차이유통계학의의(P=0.001).62례DLBCL환자중,복발자35례(56.5%).무복발조환자적miR-146b-5p표체수평명현고우복발조,차이유통계학의의(P=0.004).DLBCL환자중miR-146b-5p고표체조(>중위치)무복발생존(RFS)솔명현고우저표체조(<중위치),차이유통계학의의(P=0.005),miR-146b-5p적표체여환자총체생존(OS)솔몰유명현상관성.다인소COX모형분석현시 miR-146b-5p저표체(P=0.004)、국제예후지수(IPI)≥3분(P=0.011)위각자독립적예후불량인소.결론 DLBCL환자무복발조miR-146b-5p적표체수평명현고우복발조,병차miR-146b-5p고표체조RFS솔명현고우저표체조.제시miR-146b-5p가능시DLBCL환자풍험평고중적일개신형분자표지물.
Objective To study the expression of miR-146b-5p in diffuse large B cell lymphoma (DLBCL), and its relationship with risk assessment. Methods 62 cases of nodal DLBCL with follow-up data were collected from Shanxi Cancer Hospital, and were studied by using immunohistochemical EnVision method for CD3, CD10, CD20, Bcl-6 and MUM1. The DLBCLs were classified into germinal center B cell-like (GCB) and non-germinal center B cell-1ike (non-GCB) subtypes according to Hans’algorithm. Agilent Human miRNA Microarray 16.0 was used to select the miRNAs on paraffin-embedded tissues of 24 DLBCL cases. A TaqMan real-time polymerase chain reaction ( RT-PCR) method was performed on 62 nodal DLBCL cases to validate the expression levels of miR-146b-5p.11 cases with reactive lymph node were elected as control. Results In 62 cases of DLBCL, 35.5% of cases were GCB and 64.5% non-GCB subtypes, the expression of miR-146b-5p in GCB was 3.2 times as much as non-GCB subtypes（P=0.006). The expression of miR-146b-5p was up-regulated in DLBCL, and expression level of miR-146b-5p was 5.4 times as much as reactivated lymph node. In 62 cases of DLBCL, 43.5% cases were recurrence-free and 56.5% recurrence. The expression of miR-146b-5p was remarkably up-regulated in recurrence-free group compared with recurrence group（P=0.004). Moreover, high expression levels of miR-146b-5p in DLBCL were found to be associated with longer relapse-free survival (P=0.005), but not for overall survival. Multivariate COX proportional hazard regression analysis revealed that low expression of miR-146b-5p (P=0.004）and IPI≥3（P=0.011） were independent poor prognostic factors in 62 cases of DLBCL. Conclusions The expression of miR-146b-5p was up-regulated in recurrence-free group，and its higher expression levels in DLBCL were associated with improved relapse-free survival. Our results suggested that miR-146b-5p might be one of markers for risk assessment.
